Show simple item record

dc.contributor.authorKalverdijk, L.J.
dc.contributor.authorBachmann, C.J.
dc.contributor.authorAagaard, L.
dc.date.accessioned2019-07-15T16:12:10Z
dc.date.available2019-07-15T16:12:10Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85030848416&doi=10.1186%2fs13034-017-0192-1&partnerID=40&md5=536494a6460bda79a0d72418253a52e4
dc.identifier.urihttp://hdl.handle.net/10713/9925
dc.description.abstractOver the last decades, an increase in antipsychotic (AP) prescribing and a shift from first-generation antipsychotics (FGA) to second-generation antipsychotics (SGA) among youth have been reported. However, most AP prescriptions for youth are off-label, and there are worrying long-term safety data in youth. The objective of this study was to assess multinational trends in AP use among children and adolescents. A repeated cross-sectional design was applied to cohorts from varied sources from Denmark, Germany, the Netherlands, the United Kingdom (UK) and the United States (US) for calendar years 2005/2006-2012. The annual prevalence of AP use was assessed, stratified by age group, sex and subclass (FGA/SGA). The prevalence of AP use increased from 0.78 to 1.03% in the Netherlands' data, from 0.26 to 0.48% in the Danish cohort, from 0.23 to 0.32% in the German cohort, and from 0.1 to 0.14% in the UK cohort. In the US cohort, AP use decreased from 0.94 to 0.79%. In the US cohort, nearly all ATP dispensings were for SGA, while among the European cohorts the proportion of SGA dispensings grew to nearly 75% of all AP dispensings. With the exception of the Netherlands, AP use prevalence was highest in 15-19 year-olds. So, from 2005/6 to 2012, AP use prevalence increased in all youth cohorts from European countries and decreased in the US cohort. SGA were favoured in all countries' cohorts. Copyright 2017 The Author(s).en_US
dc.description.urihttps://www.doi.org/10.1186/s13034-017-0192-1en_US
dc.language.isoen_USen_US
dc.publisherBioMed Central Ltd.en_US
dc.relation.ispartofChild and Adolescent Psychiatry and Mental Health
dc.subjectAdolescentsen_US
dc.subjectAntipsychotic drugsen_US
dc.subjectAtypicalen_US
dc.subjectChildrenen_US
dc.subjectDenmarken_US
dc.subjectGermanyen_US
dc.subjectNetherlandsen_US
dc.subjectPharmacoepidemiologyen_US
dc.subjectUKen_US
dc.subjectUSAen_US
dc.titleA multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012en_US
dc.typeArticleen_US
dc.identifier.doi10.1186/s13034-017-0192-1


This item appears in the following Collection(s)

Show simple item record